Efficacy of I-131 Treatment Dosage for Hyperthyroidism With Current Institution Formula

Background: I-131 (radioactive iodine (RAI)) therapy effectively targets overactivity of the thyroid gland; however, literature provides conflicting outcomes regarding dosage optimization for patients with hyperthyroidism and associated clinical complications. This retrospective study aimed to validate therapeutic efficacy an empirically derived institution formula in resolving by establishing a euthyroid or hypothyroid state. Methods: chart review was undertaken 89 adult (> 18 years) who received from 2016 2020 at H&H/Queens, New York. The dose range determined accordance their gland weight uptake percentages; follow-up assessment performed duration 6 - 12 months. IRB approval reference HS-STUDY-21-01760 obtained. All subjects consented using written consent document private room. patient’s data are stored confidentially password-protected computer, which is accessible only group. primary endpoint (i.e., treatment success) defined interim development state, hypothyroidism, subclinical/questionable/suspected questionable secondary endpoints included frequency repeat RAI doses post-ablation function tests (TFTs). Results: univariate multivariate analysis patient indicated 83% success rate achievement state hypothyroidism 6.7% 70.8% patients, along attainment status, subclinical suspected 1.1%, 2.2%, 1.1% respectively. In addition, low number 9%) required dosages achieve results clinically significant impact on thyroid-stimulating hormone (TSH), triiodothyronine (T3), free thyroxin (FT4) levels. Conclusion: this testified current institution’s treating hyperthyroidism. retreatment requirement strengthened evidence favoring J Endocrinol Metab. 2023;13(2):49-56 doi: https://doi.org/10.14740/jem874